The OTC market offers unique investment opportunities beyond the traditional exchanges. In this article, we delve into the exciting realm of the OTC market to explore four active stocks that have captured the attention of investors. These stocks could provide astute investors with the potential for significant growth and returns.

Epazz, Inc. (OTC: EPAZ)

EPAZ has seen interest from investors with its diverse portfolio and innovative approach to technology solutions. As a mission-critical provider of drone technology, artificial intelligence processes, blockchain mobile apps, and cloud-based business software solutions, EPAZ offers a comprehensive range of offerings that cater to the evolving needs of various industries.

One key component that sets EPAZ apart is its subsidiary, ZenaDrone Inc., which has positioned itself as a key player in the dynamic and rapidly growing drone sector. ZenaDrone specializes in the development and marketing of cutting-edge drone technologies tailored for commercial and industrial applications. The flagship product, the ZenaDrone 1000, has garnered significant attention for its advanced features and versatile applications across sectors such as agriculture, oil and gas, civil engineering, and wildfire management.

The ZenaDrone 1000 boasts an array of impressive capabilities, including a high-quality camera, autonomous flight capabilities, and a multi-sensor system for precise measurements. This enables users to capture stunning aerial photographs and videos, even in challenging weather conditions. Moreover, the drone's ability to accurately monitor plant health, perform efficient weed spraying, and assist in various inspection and surveillance tasks has solidified its reputation as a reliable and indispensable tool.

The drone industry is taking notice of ZenaDrone's advancements, and the company has been invited to collaborate with the U.S. Air Force on battlefield tests. This collaboration focuses on utilizing the ZenaDrone 1000 platform for transporting life-saving blood to troops in the field, showcasing the trust and confidence placed in ZenaDrone's capabilities and its potential impact in critical situations.

Furthermore, EPAZ's recent establishment of a spinoff company, Galaxy Batteries Inc., demonstrates its commitment to staying at the forefront of emerging technologies. With a focus on high-powered batteries for specialized devices and aircraft, EPAZ aims to play a significant role in the evolving battery industry.

Last month, Galaxy Batteries, Inc. filed for a patent for the Artificial Intelligence Smart Battery Technology for ZenaDrone 1000 and Electric Airplanes. The battery is capable of gathering data from the environment, such as wind speed, humidity, temperature, and pressure, to optimize system performance. The AI smart battery is designed to maximize flight time for the ZenaDrone 1000 and extend battery duration for other devices. By continuously monitoring and adjusting output, voltage, and battery health, the AI smart battery ensures optimal performance in changing conditions.

With a robust portfolio of innovative technologies, a strong presence in the drone industry, a focus on AI and blockchain, and the pursuit of advancements in battery technology, EPAZ positions itself as a potentially attractive investment opportunity. The company's dedication to delivering cutting-edge solutions, securing strategic partnerships, and continually expanding its operations sets the stage for potential long-term returns.

The Greater Cannabis Company (OTC: GCAN)

GCAN is a biopharmaceutical company focused on developing innovative treatments using cannabis. They're currently conducting research and clinical trials to create effective cannabis-based therapies for different medical conditions, with a particular emphasis on neuropsychiatric disorders.

Recently, GCAN received final approval from the Israel Ministry of Health for a Phase II Clinical Trial to study the effects of their cannabinoid therapy on Autism Spectrum Disorder (ASD). The trial, led by Dr. Adi Aran, aims to evaluate the therapy's safety and effectiveness in children aged 4 to 13. They'll assess how it impacts behavior and the core symptoms of ASD using various measurements.

ASD is a lifelong condition affecting millions of people worldwide, and existing treatments often have side effects and limited effectiveness. GCAN's therapy shows promise not only for ASD but also for related disorders like Parkinson's Disease, Alzheimer's Disease, schizophrenia, and epilepsy. This research has significant implications for public health, as the cost of caring for autistic individuals is projected to increase substantially.

The approval of the Phase II Clinical Trial is a major milestone for GCAN, demonstrating their dedication to finding innovative solutions for complex neurological disorders. Positive results from this study could revolutionize the treatment options for ASD and similar conditions, providing much-needed relief for patients and their families. GCAN continues to make strides in research and development, further establishing the potential of their therapy as a groundbreaking treatment option.

QSTEL Inc. (OTC: IQST)

IQST operates as a wholesale carrier, providing telecommunication services to other companies. The company specializes in voice, SMS, and data solutions, catering to a diverse range of clients, including government entities, corporations, enterprises, and small and medium companies.

A notable development for QSTEL is the recent launch of its iQSTEL Metaverse application, which is backed by Artificial Intelligence (AI) technology. This groundbreaking application is now accessible on desktop browsers, as well as the App Store for iPhone and iPad and Google Play for Android devices. The iQSTEL Metaverse application, created by the subsidiary Reality Border, is a testament to QSTEL's dedication to advancing virtual reality and digital communication.

By leveraging AI technology and incorporating Non-Player Characters (NPCs), the iQSTEL Metaverse application offers users a unique and immersive experience. It aims to address fundamental human needs such as communication, virtual banking, mobility, and access to information. The application also provides businesses with an opportunity to enhance customer relations by offering immersive interactions, simplified product exploration, and a visual representation of their commercial history.

The Metaverse market is expected to grow to over $900 billion by 2030, presenting significant growth potential. QSTEL's entry into this market reflects the company's commitment to diversifying its portfolio and exploring innovative sectors. With a focus on telecommunications, fintech, electric vehicles, and the Metaverse, QSTEL positions itself as a dynamic player in the telecommunications and technology industries.

QSTEL's embrace of AI technology and its entry into the Metaverse market demonstrate the company's ability to adapt to emerging trends and position itself for future success. By prioritizing the fulfillment of basic human needs in today's digital world and pursuing acquisitions and organic growth, QSTEL is committed to providing accessible tools and services to a wide range of customers.

Oncorus, Inc. (OTC: ONCR)

ONCR is an RNA medicine company focused on developing self-amplifying RNA therapies administered intravenously to improve outcomes for cancer patients. The company recently reported its financial results for the first quarter of 2023 and provided updates on its business.

Oncorus is at the forefront of pioneering a unique self-amplifying RNA platform, with its lead program, ONCR-021, expected to submit an investigational new drug application (IND) to the FDA in mid-2023. The company plans to evaluate ONCR-021 in patients with various cancers, including non-small cell lung cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, and anaplastic thyroid cancer.

In terms of financial updates, Oncorus ended the first quarter with $45.0 million in cash, cash equivalents, and investments. The company's research and development expenses decreased compared to the corresponding quarter in 2022, primarily due to the winding down of the ONCR-177 program. General and administrative expenses also decreased, mainly due to employee turnover and reduced costs. However, Oncorus reported a higher net loss for the quarter, primarily attributed to a long-lived asset impairment charge.

Despite the challenges associated with raising additional capital and pursuing strategic alternatives, Oncorus remains committed to maximizing value for its stakeholders. The company recently announced a workforce reduction plan, which will see the departure of key executives but aims to improve cost savings. However, Oncorus anticipates that its existing cash and projected cash flows may not be sufficient to meet its working capital and operational needs beyond the third quarter of 2023. The company continues to explore various strategic options, including acquisitions, mergers, divestitures, or licensing, to secure additional funding.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.

CapitalGainsReport

Mark McKelvie

Editor

Markrmckelvie@gmail.com

585-301-7700

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE